Olink® Proteomics
Drug Target Identification
-
Identify protein quantitative trait loci (pQTLs) to link genetic variation, proteins, and disease
-
Gain insight into tumor biology, mechanism of immune modulation, phenotype changes, transformation of cold to hot tumors
Biomarker Analysis & Screening
-
Analyze longitudinal biomarker data between early and later timepoints to identify key biomarkers associated with drug-sensitive to drug-resistant state transitions
Protein Response Validation in Clinical Trials
-
Predict and monitor treatment response, treatment sensitivity, and mechanism of immune resistance
-
Guide strategy to optimize response rates and identify novel targetable pathways
Exploratory Endpoints in Clinical Trials
-
Examine the association of circulating protein biomarkers with clinical outcomes
-
Predict onset and mechanism of treatment-associated toxicity, monitoring cytokine release syndrome and neurotoxicity
-
Predict recurrence and on-treatment progression in adjuvant settings
How does Olink work?
Olink’s Proximity Extension Assay (PEA) uses 2 matched antibodies per target antigen. Each antibody pair is labeled with unique DNA oligo barcodes. When the antibodies bind to the same target protein in solution, the DNA oligo strands anneal with enough stability to enable DNA extension. The DNA barcode is then amplified, and the resulting amplicons are measured by qPCR or next-generation sequencing for absolute or relative quantification.
The integration of the Olink Signature Q100 instrument allows for the high-multiplex technique of the quantification of protein biomarkers with
- Minimal clinical sample volume (as low as 1 µL of plasma/serum)
- Exceptional sensitivity and specificity
- Coverage of a broad dynamic range
- A wide range of accepted biologic sample types
Olink panels scale from midplex Olink Target 48 and Olink Target 96 down to customized Olink Focus and Olink Flex.
